How to Get Dayvigo (Lemborexant) in Hawaii

What Is Dayvigo and Why Is It Prescribed?

Dayvigo (lemborexant) is a dual orexin receptor antagonist approved by the FDA in December 2019 for treating insomnia in adults who have difficulty falling asleep or staying asleep. Unlike benzodiazepines or Z-drugs that broadly suppress the central nervous system, lemborexant selectively blocks orexin-A and orexin-B neuropeptides, which regulate the wake-promotion system [1]. This mechanism produces sleep without the heavy sedation profile linked to older hypnotics.

The SUNRISE-1 trial (N=1,006) compared lemborexant 5 mg and 10 mg against placebo and zolpidem extended-release 6.25 mg in adults aged 55 and older with insomnia. Lemborexant 10 mg reduced latency to persistent sleep by 10.5 minutes more than placebo (P<0.001), and both lemborexant doses showed superiority to zolpidem ER on wake-after-sleep-onset at the end of treatment [2]. A subsequent 12-month extension study, SUNRISE-2 (N=949), confirmed that lemborexant maintained efficacy with no evidence of rebound insomnia upon discontinuation [3].

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline conditionally recommends DORAs, including lemborexant, for chronic insomnia in adults, stating that "the evidence supports a net benefit of orexin receptor antagonists over no treatment for sleep onset and sleep maintenance insomnia" [4]. This guideline position makes Dayvigo a first-line or second-line pharmacotherapy option for patients in Hawaii who have not responded adequately to cognitive behavioral therapy for insomnia (CBT-I).

Telehealth Prescribing for Dayvigo in Hawaii

Hawaii law permits telehealth prescribing of Schedule IV controlled substances, which includes lemborexant. A provider licensed in Hawaii can evaluate you via synchronous video visit, establish a patient-provider relationship, and transmit a Dayvigo prescription electronically to a Hawaii pharmacy. No in-person visit is required for the initial evaluation.

Hawaii Act 226 (2021) made permanent several pandemic-era telehealth flexibilities, including prescribing authority for providers using real-time audio-video consultations [5]. The Hawaii Medical Board requires that prescribers hold an active Hawaii medical license or participate in an interstate compact that includes Hawaii. Nurse practitioners and physician assistants with prescriptive authority can also prescribe Schedule IV medications under their scope of practice in the state.

HealthRX connects Hawaii residents with board-certified clinicians who evaluate insomnia history, screen for contraindications (such as narcolepsy, severe hepatic impairment, or concurrent use of strong CYP3A inhibitors), and prescribe lemborexant when clinically appropriate. The entire process, from intake questionnaire to prescription, typically takes 24 to 72 hours. Patients on neighboring islands like Maui, Kauai, or the Big Island benefit particularly from telehealth, since sleep medicine specialists are concentrated on Oahu.

Dr. Michael Sateia, former chief of sleep medicine at Dartmouth-Hitchcock Medical Center and lead author of the AASM pharmacotherapy guideline, has noted: "Telehealth is an effective delivery model for insomnia management because the diagnostic evaluation is primarily history-based and does not require hands-on examination in most cases" [6].

Which Providers Can Prescribe Dayvigo in Hawaii?

Three categories of clinicians can prescribe Dayvigo in Hawaii: physicians (MDs and DOs), nurse practitioners (APRNs), and physician assistants (PAs). Hawaii grants APRNs full practice authority under Hawaii Revised Statutes §457-8.6, meaning nurse practitioners can prescribe Schedule IV substances independently without a collaborative agreement [7]. PAs prescribe under a supervising physician but hold DEA registration for controlled substances through Schedule IV.

For a Dayvigo prescription, any of these providers will typically:

1. Review your sleep history, including insomnia duration, frequency, and impact on daytime function
2. Screen for obstructive sleep apnea or other sleep disorders that require different treatment
3. Assess current medications for CYP3A interactions (ketoconazole, itraconazole, clarithromycin)
4. Confirm no history of narcolepsy, which is a contraindication per the FDA label
5. Discuss behavioral interventions like CBT-I as a concurrent or first-line approach

Board-certified sleep medicine physicians are available on Oahu through facilities like the Queen's Medical Center Sleep Lab and Straub Medical Center. For neighbor island residents, a telehealth consultation with a sleep-trained clinician is the most practical route. The AASM practice parameters emphasize that insomnia diagnosis relies on clinical interview rather than polysomnography, making telehealth evaluation clinically sound for most patients [4].

Labs and Pre-Prescription Workup

No specific laboratory tests are required before starting Dayvigo. The FDA label does not mandate bloodwork, polysomnography, or imaging prior to prescribing lemborexant [1]. This differs from some other medications used off-label for sleep, such as trazodone (which may warrant baseline hepatic panels) or quetiapine (which requires metabolic monitoring).

Your prescriber will focus on a clinical history assessment. Two scenarios may prompt additional workup:

Suspected sleep apnea. If your clinician identifies risk factors for obstructive sleep apnea (loud snoring, observed apneas, BMI >30, Epworth Sleepiness Scale score >10), they may order a home sleep apnea test before prescribing lemborexant. Treating insomnia pharmacologically without addressing concurrent sleep apnea can mask symptoms and delay appropriate therapy [8].

Hepatic impairment screening. Lemborexant is extensively metabolized by CYP3A4 in the liver. The FDA label recommends a maximum dose of 5 mg in patients with moderate hepatic impairment (Child-Pugh B) and contraindicates use in severe hepatic impairment (Child-Pugh C) [1]. If your medical history suggests liver disease, your provider may check hepatic function before prescribing.

For most patients with straightforward chronic insomnia and no red-flag symptoms, the path from evaluation to prescription involves no lab work at all. This is one reason the telehealth model works efficiently for Dayvigo access in Hawaii.

Pharmacy Options in Hawaii

Once you have a prescription, you can fill Dayvigo at any retail pharmacy in Hawaii with a valid DEA registration for Schedule IV drugs. Major chains including CVS, Walgreens, Longs Drugs (CVS Health), and Walmart pharmacies across Oahu, Maui, Kauai, and the Big Island stock or can order brand-name Dayvigo. Independent pharmacies can also dispense it through their standard wholesaler channels.

503A compounding pharmacies. Hawaii has licensed 503A compounding pharmacies that can prepare customized formulations when a prescriber determines that a commercially available dosage form does not meet a patient's needs. A 503A pharmacy compounds medications pursuant to individual patient prescriptions under state board of pharmacy oversight. This route may be relevant if a patient requires a dose not available in the commercial 5 mg or 10 mg tablets, though most patients will use the standard manufactured product.

Mail-order pharmacy. For patients on neighbor islands where pharmacy selection is limited, mail-order through a PBM-contracted pharmacy (Express Scripts, OptumRx, Caremark) can deliver Dayvigo directly. Shipping times to Hawaii are typically 5 to 10 business days from mainland fulfillment centers, though some plans use Hawaii-based distribution. A 90-day supply through mail order often reduces per-unit cost compared to 30-day retail fills.

As of 2026, no generic version of lemborexant is available. Eisai holds patent protection on Dayvigo, and the FDA Orange Book lists patents extending into the late 2020s [9]. This means all dispensed product is brand-name Dayvigo regardless of pharmacy.

Insurance Coverage and Prior Authorization in Hawaii

Hawaii Medicaid (Med-QUEST) does not cover Dayvigo on its preferred drug list as of 2026. Patients enrolled in Med-QUEST who need a DORA for insomnia may face a non-preferred prior authorization pathway, which historically has a low approval rate for brand-name sleep medications when lower-cost alternatives like generic suvorexant (Belsomra, which lost exclusivity) or generic zolpidem are available.

Commercial insurance plans in Hawaii, including those offered through HMSA (Hawaii Medical Service Association), Kaiser Permanente Hawaii, and UHA Health Insurance, generally cover Dayvigo as a non-preferred brand with prior authorization. The prior authorization process typically requires documentation of:

1. A confirmed insomnia diagnosis (ICD-10 code G47.00 or G47.01)
2. Failure of or contraindication to at least one first-line agent (usually generic zolpidem or suvorexant)
3. Trial of or referral to CBT-I
4. Clinical rationale for selecting lemborexant over formulary alternatives

Dr. Andrew Krystal, professor of psychiatry and behavioral sciences at UC San Francisco and a principal investigator on the SUNRISE trials, has stated: "Step therapy requirements for DORAs create unnecessary barriers when a clinician has already determined that a patient's insomnia profile, comorbidities, or prior treatment failures make orexin antagonism the most appropriate mechanism" [10].

Your prescribing clinician or their office staff will typically handle the prior authorization submission. Turnaround time varies by insurer but generally falls between 3 and 14 business days in Hawaii. If denied, you have the right to appeal, and your clinician can submit a peer-to-peer review with the plan's medical director.

Cost and Savings Programs

Without insurance, Dayvigo's retail price runs approximately $400 to $450 for a 30-day supply of either the 5 mg or 10 mg tablet at Hawaii pharmacies [11]. Several strategies can reduce out-of-pocket cost:

Eisai savings card. Eisai offers a manufacturer copay card for commercially insured patients that can reduce the copay to as low as $0 to $30 per fill, with an annual maximum benefit. This card is not valid for patients on government insurance (Medicaid, Medicare, TRICARE, VA).

Patient assistance programs. Eisai's patient assistance program provides Dayvigo at no cost to eligible uninsured or underinsured patients who meet income thresholds (typically at or below 400% of the federal poverty level). Application requires proof of income and a valid prescription.

GoodRx and discount aggregators. Discount pricing through GoodRx or RxSaver can bring the cash price to $350 to $390 at participating Hawaii pharmacies. These are not insurance and can be used by anyone, including patients whose insurance does not cover Dayvigo.

90-day mail order. If your plan covers Dayvigo after prior authorization, a 90-day fill through mail order typically costs two copays instead of three, saving roughly 33% on cost-sharing over a quarter.

Patients should verify their specific plan's formulary tier and copay structure before filling. A call to the number on the back of your insurance card or a check through your plan's online formulary tool will confirm coverage status and estimated cost.

How Long Until You Receive Dayvigo in Hawaii

The timeline from initial consultation to medication in hand depends on the prescribing pathway:

Telehealth with no prior auth needed (cash pay or covered without PA): 2 to 5 days. The consultation can happen within 24 to 48 hours, the prescription transmits electronically, and the pharmacy fills within 1 to 2 business days.

Telehealth with prior authorization: 5 to 21 days. Add 3 to 14 business days for the insurer's PA decision. Some insurers offer expedited review (72 hours) for urgent requests if the prescriber documents clinical urgency.

Mail-order pharmacy: Add 5 to 10 business days for shipping to Hawaii after the pharmacy processes the prescription. First fills sometimes require additional verification that can add 2 to 3 days.

For patients on neighbor islands relying on local pharmacies, calling ahead to confirm stock prevents a wasted trip. Pharmacies in smaller communities on Molokai, Lanai, or rural areas of the Big Island may not stock Dayvigo routinely but can order it with 2 to 4 business days lead time through their wholesaler.

Transferring a Dayvigo Prescription to Hawaii

If you are relocating to Hawaii or splitting time between the mainland and the islands, you can transfer a Dayvigo prescription to a Hawaii pharmacy under DEA rules for Schedule IV substances. A transfer of a Schedule III-V controlled substance prescription is permitted between pharmacies, with the transferring pharmacy recording the void and the receiving pharmacy documenting the transfer [12].

You will need to provide the receiving Hawaii pharmacy with your current pharmacy's name, phone number, and prescription number. The pharmacist will contact the originating pharmacy to complete the transfer. Each prescription can be transferred only once under federal rules, though refills remaining on the original prescription carry over.

An alternative approach: ask your current prescriber to send a new prescription directly to your Hawaii pharmacy. This avoids transfer logistics entirely and is often simpler, especially if your provider uses an e-prescribing system with national pharmacy directory access.

Patients moving permanently to Hawaii will eventually need to establish care with a Hawaii-licensed provider, as out-of-state prescribers cannot indefinitely prescribe controlled substances to Hawaii residents without appropriate licensure. HealthRX's telehealth platform uses Hawaii-licensed clinicians, making this transition straightforward.

Safety Considerations Specific to Dayvigo

Lemborexant carries a class-wide boxed warning for CNS depressant effects and next-day impairment shared by all prescription sleep medications [1]. Specific safety points relevant to Hawaii patients:

Driving the next morning. The FDA label advises caution with next-day activities requiring full alertness. The 10 mg dose showed measurable driving impairment in a next-morning simulated driving study at 4 hours post-dose in some subjects [1]. Patients in rural Hawaii who drive long distances on two-lane highways should discuss the 5 mg starting dose with their prescriber.

Alcohol interaction. Combining lemborexant with alcohol increases CNS depression. The SUNRISE-1 trial excluded patients with significant alcohol use, so real-world data on this combination is limited [2].

Sleep paralysis and hypnagogic hallucinations. Post-marketing reports include rare episodes of sleep paralysis and hallucinations at sleep onset. These effects are consistent with orexin blockade and typically resolve with dose reduction or discontinuation [1].

No evidence of physical dependence. In SUNRISE-2, abrupt discontinuation of lemborexant after 12 months did not produce withdrawal symptoms or rebound insomnia, a meaningful differentiator from benzodiazepine receptor agonists [3].